Interview: Patrice Carayon – CEO, Chiesi France
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
Chiesi is an international company based in Parma, with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.With a turnover of more than €1.3 billion sales, Chiesi is among the top 50 pharmaceutical companies in the world. They have production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil) and R&D centres in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK).
Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities. In 2013 Chiesi announced an investment of 22 million euros (USD 23.90 million) in their production site in Blois. Significant investments in manufacturing capacity have been made. Previously, the site employed 60 people, by the end of 2016 this number will have almost doubled.
Chiesi was established in France in 1992 through its subsidiary ProMedica. In 1999, the Italian group strengthened its presence with the acquisition of Logeais Group. Today, the French subsidiary is directed by Patrice Carayon. It represents 8 percent of total Group sales with a turnover of 104 million euros in 2014. Subsidiary of primary importance, France is Chiesi´s fifth most important market.
Contact
Address: Immeuble le Doublon – 11 Avenue Dubonnet, 92400 Courbevoie – France
Tel: 33 1 47688899
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
The basis of the pharmaceutical business model is changing. Take sales forces for instance, what will be the composition and daily routine? How much mixed media will it require? Currently,…
What has been the contribution of the LRU reform and specifically what has the Creation of Research Centers and Higher Education (PRES) done to establish universities back at the heart…
What has been the contribution of the LRU reform and specifically what has the Creation of Research Centers and Higher Education (PRES) done to establish universities back at the heart…
Can you highlight some of the more recent milestones for Stallergenes? Stallergenes has been successful over recent years for several reasons, the first of which is the growth of the…
As Quintiles is present in all major pharmaceutical markets worldwide, what’s the relevance of the French affiliate and what role it plays inside such a globalized organization? France is important…
When we met your Italian colleague, he noted that they had tripled their turnover in a five year period. You haven’t done badly yourself in the relatively short period of…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
See our Cookie Privacy Policy Here